REG - BiVictriX Therapcts. - BiVictriX Director Dealings

Bivictrix TherapeuticsAnnouncement

22/12/2021 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211222:nRSV4192Wa&default-theme=true

RNS Number : 4192W  BiVictriX Therapeutics PLC  22 December 2021

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK
VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH
LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED.  ON
PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS
INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

22 December 2021

 

BIVICTRIX THERAPEUTICS PLC

("BiVictriX" or "the Company")

 

Director Dealings

 

Alderley Park, 22 December 2021 BiVictriX Therapeutics plc (AIM: BVX), an
emerging biotechnology company applying a novel approach to develop next
generation cancer therapies using insights derived from frontline clinical
experience, announces that the following directors have dealt in the
Company's ordinary shares of 1 pence each ("Ordinary Shares"):

 

Tiffany Thorn, the Company's Chief Executive Officer, has purchased 35,000
Ordinary Shares via two transactions which are summarised in the table below:

 

 Date of transaction  Number of Ordinary Shares purchased  Price per Ordinary Share
 20 December 2021     25,000                               26p
 21 December 2021     10,000                               27p

 

Following this purchase, Mrs Thorn is benefically interested in 1,632,500
Ordinary Shares representing 2.5 per cent of the Company's issued share
capital.

 

On 20 December 2021, Susan Lowther, a Non-Executive Director of the Company,
purchased 72,727 Ordinary Shares at a price of 27.5 pence each. Following this
purchase, Mrs Lowther is benefically interested in 72,727  Ordinary Shares
representing 0.1 per cent of the Company's issued share capital.

 

 

-Ends-

 

 

 For more information, please contact:

BiVictriX Therapeutics plc
 Tiffany Thorn, Chief Executive Officer               Email: info@bivictrix.com

 Iain Ross, Chairman
                                                     Tel: +44 (0) 20 3470 0470

 SP Angel Corporate Finance LLP (NOMAD and Broker)
 David Hignell, Caroline Rowe (Corporate Finance)

 Vadim Alexandre, Rob Rees (Sales and Broking)

 Panmure Gordon (UK) Limited (Joint Broker)          Tel: +44 (0) 20 7886 2500
 Rupert Dearden/Freddy Crossley/Emma Earl

 Consilium Strategic Communications
 Ashley Tapp, Suki Virji                             Tel: +44 (0) 20 3709 5700

                           Email: Bivictrix@consilium-comms.com

 

About BiVictriX Therapeutics plc

BiVictriX is a UK-based drug discovery and development company which is
focused on leveraging clinical experience to develop a class of highly
selective, next generation cancer therapeutics which exhibit superior potency,
whilst eliminating treatment-related toxicities.

 

The Company utilises a first-in-class approach to generate a proprietary
pipeline of Bi-Cygni® therapeutics which are designed to selectively target
antigen co-expression fingerprints, or "twin antigens", on tumour cells, which
are largely absent from healthy cells. Whereas this concept has been validated
in a clinical diagnostic setting to support the diagnosis and monitoring of
haematological cancers, it has not yet been widely used in a therapeutic
setting.

 

BiVictriX has identified a diverse panel of novel cancer-specific "twin
antigens", across a broad range of cancer indications including Diffuse Large
B Cell Lymphoma, Acute Myeloid Leukaemia and Blastic Plasmacytoid Dendritic
Cell Neoplasm. The Company is using these novel "twin-antigens" to develop
more effective and safer therapeutics to target cancers that are expected to
constitute orphan indications and currently constitute areas of high unmet
medical need.

 

Find out more about BiVictriX online at www.bivictrix.com
(http://www.bivictrix.com)

 

Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them.

 1.    Details of the person discharging managerial responsibilities / person closely
       associated
 a)    Name                                                         Tiffany Thorn
 2.    Reason for the Notification
 a)    Position/status                                              Chief Executive Officer
 b)    Initial notification/Amendment                               Initial notification
 3.    Details of the issuer, emission allowance market participant, auction
       platform, auctioneer or auction monitor
 a)    Name                                                         BiVictriX Therapeutics plc
 b)    LEI                                                          213800ZI85IZNA6N3L53
 4.    Details of the transaction(s): section to be repeated for (i) each type of
       instrument; (ii) each type of transaction; (iii) each date; and (iv) each
       place where transactions have been conducted
 a)    Description of the Financial instrument, type of instrument  Ordinary Shares of 1 pence each

                                                                    GB00BNXH3K91
       Identification code
 b)    Nature of the transaction                                    Purchase of Ordinary Shares
 c)    Price(s) and volume(s)

Price(s)       Volume(s)
                                                                    1.    26p      25,000

                                                                                   10,000

                                                                    2.    27p
 d)    Aggregated information:                                      Price(s)                   Volume(s)

       -  Aggregated volume

       -  Price                                                     26.3p (weighted average)   35,000

 
 e)    Date of the transactions                                     20 - 21 December 2021
 f)    Place of the transaction                                     AIM, London Stock Exchange

d)

Aggregated information:

-  Aggregated volume

-  Price

 Price(s)                   Volume(s)

 26.3p (weighted average)   35,000

 

e)

Date of the transactions

20 - 21 December 2021

f)

Place of the transaction

AIM, London Stock Exchange

 

 1.    Details of the person discharging managerial responsibilities / person closely
       associated
 a)    Name                                                         Susan Lowther

 2.    Reason for the Notification
 a)    Position/status                                              Non-Executive Director
 b)    Initial notification/Amendment                               Initial notification
 3.    Details of the issuer, emission allowance market participant, auction
       platform, auctioneer or auction monitor
 a)    Name                                                         BiVictriX Therapeutics plc
 b)    LEI                                                          213800ZI85IZNA6N3L53
 4.    Details of the transaction(s): section to be repeated for (i) each type of
       instrument; (ii) each type of transaction; (iii) each date; and (iv) each
       place where transactions have been conducted
 a)    Description of the Financial instrument, type of instrument  Ordinary Shares of 1 pence each

                                                                    GB00BNXH3K91
       Identification code
 b)    Nature of the transaction                                    Purchase of Ordinary Shares
 c)    Price(s) and volume(s)

Price(s)  Volume(s)
                                                                    27.5p     72,727
 d)    Aggregated information:                                      Price(s)  Volume(s)

                                                            27.5p     72,727
       -  Aggregated volume

       -  Price
 e)    Date of the transaction                                      20 December 2021
 f)    Place of the transaction                                     AIM, London Stock Exchange

d)

Aggregated information:

-  Aggregated volume

-  Price

 Price(s)  Volume(s)
 27.5p     72,727

e)

Date of the transaction

20 December 2021

f)

Place of the transaction

AIM, London Stock Exchange

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHMZMZZZMRGMZZ